Linked Life Data

1386349

Source:http://linkedlifedata.com/resource/pubmed/id/1386349

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1992-8-31
pubmed:abstractText
We investigated the optimal culture conditions (i.e., activation procedure, medium composition and type of culture vessel) for rapid in vitro expansion of large numbers (greater than 5 x 10(9) of blood T lymphocytes. These expanded lymphocytes can be targeted to be cytotoxic to ovarian carcinoma cells with a bispecific monoclonal antibody (BsAb) specific for CD3 and for the ovarian carcinoma-associated antigen MOv18. Both phytohemagglutinin (PHA) and monoclonal antibody (MAb) CD3 induced rapid T-cell proliferation, although the growth kinetics after PHA activation were slightly faster. A 50-fold increase in cell number was obtained after 14 and 16 days for PHA and CD3 MAb, respectively. The induction of BsAb-directed cytolysis was faster after CD3 MAb than after PHA activation of lymphocytes, but became similar around day 20. A mixture of media consisting of 78% RPMI 1640, 20% AIM-V and 2% human plasma (Mix-med) yielded better results than 100% AIM-V medium. Culture of lymphocytes in polyolefin bags, compared with tissue culture flasks, or cryopreservation did not affect lymphocyte yield and function. In most cultures the proportion of CD8+ lymphocytes increased, suggesting a growth advantage of CD8+ over CD4+ lymphocytes in this culture system. A protocol employing PHA activation, Mix-med and polyolefin bags has been used successfully to activate and expand blood lymphocytes for the first 5 patients entered into a phase-I/II clinical trial for the intraperitoneal treatment of ovarian carcinoma using CD3 x anti-MOv18 BsAb-directed T lymphocytes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
51
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
973-9
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:1386349-Antibodies, Monoclonal, pubmed-meshheading:1386349-Antigens, CD, pubmed-meshheading:1386349-Antigens, CD3, pubmed-meshheading:1386349-Antigens, CD8, pubmed-meshheading:1386349-Antigens, Differentiation, T-Lymphocyte, pubmed-meshheading:1386349-Antigens, Neoplasm, pubmed-meshheading:1386349-Culture Media, pubmed-meshheading:1386349-Culture Techniques, pubmed-meshheading:1386349-Cytotoxicity, Immunologic, pubmed-meshheading:1386349-Humans, pubmed-meshheading:1386349-Immunophenotyping, pubmed-meshheading:1386349-Immunotherapy, pubmed-meshheading:1386349-Kinetics, pubmed-meshheading:1386349-Lymphocyte Activation, pubmed-meshheading:1386349-Phytohemagglutinins, pubmed-meshheading:1386349-Receptors, Antigen, T-Cell, pubmed-meshheading:1386349-T-Lymphocyte Subsets, pubmed-meshheading:1386349-T-Lymphocytes
pubmed:year
1992
pubmed:articleTitle
Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
pubmed:affiliation
Department of Immunology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't